• Skip to content
  • Accessibility help
Skip to content
Sign in
  • Guidance
  • Skip Standards and indicators submenu

    Quality standards

    Our quality standards set out priority areas for quality improvement. They highlight areas with identified variation in current practice.

    View our quality standards

    • How to use our quality standards
    • The timeline for developing quality standards
    • Help us develop quality standards
    • Selecting and prioritising quality standards topics
    • About quality standards

    Indicators

    Our indicators measure outcomes that reflect the quality of care, or processes linked by evidence to improved outcomes.

    View list of indicators

    • Learn about the committee that develops indicators
    • About indicators
  • Skip Life sciences submenu

    Life Sciences

    We offer tailored support to industry during product development. Our expertise can help you build the evidence needed to achieve market access.

    View life sciences

    Get support from NICE

    NICE Advice service

    Trusted, unrivalled expertise.

    Make an enquiry

    Contact us to discuss your requirements.

    Innovative Licensing and Access Pathway (ILAP)

    Streamlining patient access to safe, financially sustainable and innovative medicines.

    Learn how we evaluate technologies

    Health technology evaluation and topic selection manuals

    Updated manuals for methods, processes and topic selection.

    Digital health technologies

    Accelerating our efforts to deliver innovation to the health and care system.

    Evidence standards framework

    Using the best available evidence to develop recommendations that guide decisions in health, public health and social care.

    Our guidance programmes

    Ensuring new technologies are clinically effective and offer economic value.

    Register your product

    Non-pharmaceutical

    NHS Innovation Service is a clear and simple point of entry for health technologies to access support and national evaluation programmes.

    Pharmaceutical

    UK PharmaScan is a database of new medicines, indications and formulations in the pharmaceutical pipeline.

    Find published and proposed evaluations

    Diagnostics

    Guidance on measurements and tests used to evaluate a patient's condition.

    Medical technologies

    Guidance on medical technologies put forward to NICE by manufacturers.

    Technology appraisals

    Guidance on new and existing medicines and treatments in the NHS.

    Highly specialised technologies

    Guidance on the use of highly specialised medicines and treatments.

  • British National Formulary (BNF)
  • British National Formulary for Children (BNFC)
  • Clinical Knowledge Summaries (CKS)
  • Skip About submenu

    About

    NICE helps practitioners and commissioners get the best care to patients, fast, while ensuring value for the taxpayer.

    Explore about

    Our programmes

    Learn about the information we produce.

    • Guidance
    • Advice
    • Quality standards
    • Indicators
    • Digital health
    • Topic selection

    Get involved

    • Understand how decisions are made:

      Attend a committee meeting
    • Comment on draft guidance:

      Guidance in consultation
    • Be part of a guidance committee:

      Join a committee
    • Help develop our products:

      Register as a stakeholder
    • Putting you at the heart of our work:

      Public involvement

    What we do

    • Social care
    • Life sciences
    • NICE international
    • Patient safety
    • Shared decision making
    • View all What we do

    Into practice

    • Social care quick guides
    • Measuring the use of NICE guidance
    • Resource planner
    • View all Into practice

    Who we are

    • The board
    • The NICE strategy 2021 to 2026
    • Corporate publications
    • View all Who we are

    • Contact us
    • Jobs

My account

  • Consultation responses
  • Sign in

You are here:

  1. Home
  2. NICE Guidance
  3. Conditions and diseases
  4. Neurological conditions
  5. Epilepsy

Epilepsies in children, young people and adults

  • NICE guideline
  • Reference number: NG217
  • Published:  27 April 2022
  • Last updated:  30 January 2025
  • Guidance
  • Tools and resources
  • Information for the public
  • Evidence
  • History
Download guidance (PDF)
  • Overview
  • 1 Diagnosis and assessment of epilepsy
  • 2 Information and support
  • 3 Referral to tertiary specialist services
  • 4 Principles of treatment, safety, monitoring and withdrawal
  • 5 Treating epileptic seizures in children, young people and adults
  • 6 Treating childhood-onset epilepsies
  • 7 Treating status epilepticus, repeated or cluster seizures, and prolonged seizures
  • 8 Non-pharmacological treatments
  • 9 Psychological, neurobehavioural, cognitive and developmental comorbidities in epilepsy
  • 10 Reducing the risk of epilepsy-related death including sudden unexpected death in epilepsy
  • 11 Service provision and transition
  • Terms used in this guideline
  • Recommendations for research
  • Rationale and impact
  • Context
  • Finding more information and committee details
  • Update information

On this page

  1. 10.1 Risk factors
  2. 10.2 Interventions

10 Reducing the risk of epilepsy-related death including sudden unexpected death in epilepsy

10.1 Risk factors

10.1.1

Be aware that epilepsy is associated with an increased risk of premature death, including a risk of sudden unexpected death in epilepsy (SUDEP).

10.1.2

Be aware that potentially modifiable risk factors for SUDEP include:

  • non-adherence to medication

  • alcohol and drug misuse

  • having focal to bilateral tonic-clonic seizures or generalised tonic-clonic seizures

  • having uncontrolled seizures

  • living alone

  • sleeping alone without supervision.

10.1.3

Be aware that the risk of epilepsy-related death is increased in people with:

  • previous brain injury

  • previous central nervous system infection

  • metastatic cancer

  • previous stroke

  • abnormal neurological examination findings.

10.1.4

Discuss with people with epilepsy, and their families and carers if appropriate, their individual risk of epilepsy-related death, including SUDEP, from the time of diagnosis onwards. For young children, this discussion should be with the child's parents or carers. Discussion should include:

  • supporting them to understand the risks of epilepsy-related death, including SUDEP

  • exploring and agreeing ways to reduce the risks.

10.1.5

Discuss the risk of SUDEP with people who have seizures during sleep and, if appropriate, include their families and carers. Provide information on minimising risks, including taking their medication as prescribed.

10.2 Interventions

10.2.1

Discuss the possibility of introducing or increasing night-time supervision, for example, a parent or carer may wish to use a night monitor for people with epilepsy who have seizures during sleep and have been assessed to be at higher risk of epilepsy-related death.

10.2.2

Support people with epilepsy to take their medications as prescribed to reduce seizures. Explain that uncontrolled seizures increase the risk of epilepsy-related death, particularly for people with generalised tonic-clonic seizures or focal to bilateral tonic-clonic seizures. Follow the recommendations in NICE's guideline on medicines adherence.

For a short explanation of why the committee made these recommendations and how they might affect practice, see the rationale and impact section on reducing the risk of epilepsy-related death including sudden unexpected death in epilepsy .

Full details of the evidence and the committee's discussion are in the following evidence reviews:

  • evidence review 17: prediction of death, including SUDEP, in people with epilepsy

  • evidence review 18: modifiable risk factors for epilepsy related mortality

  • evidence review 19: reducing the risk of seizure-related mortality, including SUDEP.

Loading. Please wait.


Next page 11 Service provision and transition Previous page 9 Psychological, neurobehavioural, cognitive and developmental comorbidities in epilepsy
Back to top
  • Guidance
  • Standards and indicators
  • Life sciences
  • British National Formulary (BNF)
  • British National Formulary for Children (BNFC)
  • Clinical Knowledge Summaries (CKS)
  • Knowledge resources
  • About NICE
  • Into practice
  • Get involved with NICE
  • Jobs
  • News
  • Newsletters and alerts
  • Contact us
  • Leave feedback
  • Reusing our content
  • NICE UK Open Content Licence
  • Syndicate our content
  • Events
  • Facebook
  • X
  • YouTube
  • LinkedIn
  • Accessibility
  • Freedom of information
  • Glossary
  • Terms and conditions
  • Privacy notice
  • Cookies

© NICE 2025. All rights reserved. Subject to Notice of rights.